# Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR

Study · id `cardio:ct-nct06689839` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06689839](<https://clinicaltrials.gov/study/NCT06689839>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06689839

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 500 participants.

## Technical summary

Registry record NCT06689839. Randomized; single masking; primary purpose treatment. Start 2025-09-09 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT06689839, source copy `cardio:ctgov-nct06689839-2026-11-06`, retrieved 2026-11-18)
- Started: 2025-09-09 (actual) (ClinicalTrials.gov record NCT06689839, source copy `cardio:ctgov-nct06689839-2026-11-06`, retrieved 2026-11-18)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT06689839, source copy `cardio:ctgov-nct06689839-2026-11-06`, retrieved 2026-11-18)
- Completion: 2027-01 (anticipated) (ClinicalTrials.gov record NCT06689839, source copy `cardio:ctgov-nct06689839-2026-11-06`, retrieved 2026-11-18)
- Countries: United States; Australia (ClinicalTrials.gov record NCT06689839, source copy `cardio:ctgov-nct06689839-2026-11-06`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06689839-2026-11-06`, retrieved 2026-11-18)

## The registry's words

- Brief title: Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
- Acronym: SHIELD
- Condition: Aortic Stenosis Treated With TAVI
- Condition: Aortic Diseases
- Intervention (Device): F2 Filter and Delivery System
- Intervention (Procedure): Transcatheter Aortic Valve Replacement (TAVR)
- Lead sponsor: EnCompass Technologies, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: DP Clinical, Inc.
- Collaborator class: INDUSTRY
- Collaborator: Avania Pty Ltd
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)

## Provenance

Content hash: 103c3e27149851947f8679befcbf5d0fb29ab838231464a422b3c71c0be823df
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
